Cingulate (CING) Competitors $4.30 -0.05 (-1.04%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$4.30 0.00 (0.00%) As of 07/3/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. IGMS, INCR, IMUX, ICCC, BMEA, STRO, ADAP, SKYE, IKNA, and CLSDShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include IGM Biosciences (IGMS), InterCure (INCR), Immunic (IMUX), ImmuCell (ICCC), Biomea Fusion (BMEA), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Skye Bioscience (SKYE), Ikena Oncology (IKNA), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors IGM Biosciences InterCure Immunic ImmuCell Biomea Fusion Sutro Biopharma Adaptimmune Therapeutics Skye Bioscience Ikena Oncology Clearside Biomedical IGM Biosciences (NASDAQ:IGMS) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings. Is IGMS or CING more profitable? Cingulate has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Cingulate's return on equity of -229.78% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,417.79% -317.97% -71.43% Cingulate N/A -229.78%-142.28% Which has more risk and volatility, IGMS or CING? IGM Biosciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.79, suggesting that its stock price is 179% less volatile than the S&P 500. Does the media refer more to IGMS or CING? In the previous week, IGM Biosciences had 6 more articles in the media than Cingulate. MarketBeat recorded 6 mentions for IGM Biosciences and 0 mentions for Cingulate. IGM Biosciences' average media sentiment score of 0.46 beat Cingulate's score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media. Company Overall Sentiment IGM Biosciences Neutral Cingulate Neutral Which has stronger earnings and valuation, IGMS or CING? Cingulate has lower revenue, but higher earnings than IGM Biosciences. Cingulate is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M30.22-$195.79M-$3.27-0.41CingulateN/AN/A-$15.55M-$8.48-0.51 Do institutionals and insiders hold more shares of IGMS or CING? 42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate IGMS or CING? IGM Biosciences presently has a consensus target price of $5.50, suggesting a potential upside of 305.90%. Cingulate has a consensus target price of $26.00, suggesting a potential upside of 505.36%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryIGM Biosciences beats Cingulate on 9 of the 15 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.17M$2.90B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-0.5121.5627.5120.24Price / SalesN/A281.76416.89118.64Price / CashN/A42.7336.8958.07Price / Book1.857.518.035.67Net Income-$15.55M-$55.05M$3.18B$249.13M7 Day Performance6.05%4.61%2.90%3.28%1 Month Performance1.30%4.72%3.71%5.56%1 Year Performance1,157.32%5.92%36.03%21.13% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.3252 of 5 stars$4.30-1.0%$26.00+505.4%+1,242.2%$18.17MN/A-0.5120IGMSIGM Biosciences4.4259 of 5 stars$1.16-0.9%$5.50+374.1%-79.0%$69.94M$2.68M-0.35190News CoverageINCRInterCure0.4715 of 5 stars$1.52+0.3%N/A-30.0%$69.27M$66.28M0.00350Gap UpIMUXImmunic2.8563 of 5 stars$0.71-1.7%$11.60+1,538.4%-36.3%$68.99MN/A-0.5870Positive NewsICCCImmuCell0.3042 of 5 stars$6.65-12.5%N/A+56.9%$68.68M$26.49M-94.9970News CoverageHigh Trading VolumeBMEABiomea Fusion2.5916 of 5 stars$1.69-6.6%$21.40+1,166.3%-62.0%$68.01MN/A-0.4850STROSutro Biopharma3.2192 of 5 stars$0.80-0.3%$6.11+665.4%-73.4%$67.64M$62.04M-0.27240ADAPAdaptimmune Therapeutics2.1434 of 5 stars$0.24-4.2%$1.52+526.4%-75.4%$67.06M$178.03M-0.90490SKYESkye Bioscience2.5376 of 5 stars$2.87+66.0%$16.60+478.2%-38.7%$66.90MN/A-3.5011IKNAIkena Oncology2.43 of 5 stars$1.34-1.5%$3.00+123.9%-18.4%$65.63M$9.16M-1.5670CLSDClearside Biomedical1.4355 of 5 stars$0.82-2.3%$4.80+485.1%-35.3%$65.26M$1.66M-2.0030 Related Companies and Tools Related Companies IGM Biosciences Competitors InterCure Competitors Immunic Competitors ImmuCell Competitors Biomea Fusion Competitors Sutro Biopharma Competitors Adaptimmune Therapeutics Competitors Skye Bioscience Competitors Ikena Oncology Competitors Clearside Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
